Corvus Pharmaceuticals Reports Leadership and Compensation Changes
Ticker: CRVS · Form: 8-K · Filed: Oct 2, 2025 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $35,000, $6,000, $4,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
Related Tickers: CRVS
TL;DR
Corvus Pharma (CRVS) filed an 8-K detailing board and exec comp changes. Watch for leadership impact.
AI Summary
Corvus Pharmaceuticals, Inc. filed an 8-K on October 2, 2025, reporting changes in its board of directors and certain officers, along with updates to compensatory arrangements. The filing indicates a shift in the company's leadership structure and executive compensation policies.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or governance adjustments that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive and board composition can introduce uncertainty regarding future strategy and operational direction.
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Registrant
- October 2, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the excerpt.
Were there any new officers appointed?
Yes, the filing mentions 'Appointment of Certain Officers' as an item of disclosure.
What is the nature of the updates to compensatory arrangements?
The filing lists 'Compensatory Arrangements of Certain Officers' as a disclosed item, suggesting updates or new information regarding executive pay.
What is Corvus Pharmaceuticals' principal executive office address?
The principal executive offices are located at 901 Gateway Boulevard, Third Floor, South San Francisco, CA 94080.
When is Corvus Pharmaceuticals' fiscal year end?
Corvus Pharmaceuticals' fiscal year ends on December 31.
Filing Stats: 699 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2025-10-02 16:37:55
Key Financial Figures
- $0.0001 — ich registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market
- $35,000 — director, Mr. Moore will receive (i) a $35,000 annual retainer for his service on the
- $6,000 — additional annual cash compensation of $6,000 for his service as a member of the Comp
- $4,000 — additional annual cash compensation of $4,000 for his service as a member of the Nomi
Filing Documents
- crvs-20251002x8k.htm (8-K) — 35KB
- 0001104659-25-096103.txt ( ) — 141KB
- crvs-20251002.xsd (EX-101.SCH) — 3KB
- crvs-20251002_lab.xml (EX-101.LAB) — 15KB
- crvs-20251002_pre.xml (EX-101.PRE) — 10KB
- crvs-20251002x8k_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 2, 2025, the Board of Directors (the "Board") of Corvus Pharmaceuticals, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee (the "Nominating Committee"), appointed David Moore to the Board. Mr. Moore was appointed as a Class III director with a term expiring at the 2028 annual meeting of stockholders and until his successor is elected and qualified, or until his earlier death, resignation or removal. Mr. Moore was also appointed to the Compensation Committee of the Board (the "Compensation Committee") and the Nominating Committee, effective October 2, 2025. Pursuant to the Company's non-employee director compensation program, as a non-employee director, Mr. Moore will receive (i) a $35,000 annual retainer for his service on the Board, earned on a quarterly basis and prorated for the remainder of the current calendar quarter and (ii) an automatic initial grant of a stock option to purchase 30,000 shares of Common Stock under the Company's 2016 Equity Incentive Award Plan. Mr. Moore will receive additional annual cash compensation of $6,000 for his service as a member of the Compensation Committee and an additional annual cash compensation of $4,000 for his service as a member of the Nominating Committee, both earned on a quarterly basis and prorated for the remainder of the current calendar quarter. Mr. Moore will also be eligible for subsequent equity awards in accordance with the Company's non-employee director compensation program. The foregoing description is qualified in its entirety by reference to the text of the Company's non-employee director compensation program, the form of which was filed as Exhibit 10.12 to the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 25, 2025. In add
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORVUS PHARMACEUTICALS, INC. Date: October 2, 2025 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer